S-1: INVO Fertility Registers 7.37M Shares for Resale, Acquires Family Beginnings

Sentiment:

Resale Registration Statement 17 December 2025 4:42 PM

INVO Fertility, Inc. filed an S-1 registration statement for the resale of up to 7.37 million common shares by existing stockholders and announced the acquisition of fertility practice Family Beginnings for $750,000.

Delay expectedThe closing of the Family Beginnings acquisition is expected by February 27, 2026. If it does not occur by this date, the Asset Purchase Agreement will automatically terminate unless an extension is agreed upon.If the Family Beginnings acquisition closes after January 31, 2026, the cash portion of the purchase price will increase by $10,000, indicating a potential financial penalty for delay.

Capital raiseThe company may receive up to $8,056,233.87 upon the exercise of the Common Warrant, Pre-Funded Warrant, and Placement Agent Warrant.Five Narrow Lane LP (FNL) has an "Additional Investment Right" to purchase up to $10 million of aggregate stated value of additional Series C-2 Preferred shares.Armistice Capital Master Fund Ltd. purchased approximately $4,000,000 worth of common stock and warrants in a private placement on December 2, 2025.

Worse than expectedThe company's auditor, M&K CPAs, PLLC, included an explanatory paragraph in their report regarding the company's ability to continue as a going concern, indicating financial uncertainty.The registration of a large number of shares for resale by selling stockholders, combined with various warrant exercises and convertible preferred stock, poses a significant risk of substantial dilution to existing shareholders and potential downward pressure on the stock price.The conversion price of Series C-2 Preferred is subject to reduction based on market prices, which could lead to further dilution at unfavorable terms for current investors.

Summary

INVO Fertility, Inc. (IVF) filed an S-1 registration statement for the resale of up to 7,372,122 shares of common stock by existing selling stockholders, including Five Narrow Lane LP, Armistice Capital Master Fund Ltd., and Maxim Partners LLC.
The company will not receive proceeds from the sale of shares by selling stockholders but may receive up to $8,056,233.87 upon the exercise of associated warrants.
INVO Fertility is acquiring Family Beginnings, a fertility practice in Indianapolis, Indiana, for a combined purchase price of $750,000, consisting of $350,000 cash (less a $150,000 holdback) and 4,000 shares of Series D Non-Voting Convertible Preferred Stock valued at $400,000.
The acquisition of Family Beginnings is expected to close by February 27, 2026, with a $10,000 increase in the cash portion if closing occurs after January 31, 2026.
The company's common stock was trading at $1.18 per share on the Nasdaq Capital Market as of December 16, 2025.
INVO Fertility's business strategy focuses on expanding access to assisted reproductive technology (ART) care by building, acquiring, and operating fertility clinics, including INVO Centers and profitable IVF clinics, and distributing its INVOcell medical device.

Sentiment

Score: 4

Explanation: While the company is pursuing strategic acquisitions and growth in the fertility market, the significant potential for dilution from the registered resale shares and various warrants, coupled with the 'going concern' warning from auditors, creates considerable uncertainty and downside risk for investors. The acquisition of Family Beginnings is a positive strategic move, but its benefits are prospective and subject to integration risks.

Positives

The strategic acquisition of Family Beginnings expands the company's clinic network and service offerings in the fertility market.
The acquisition of Wisconsin Fertility Institute in August 2023 more than tripled annual revenue and added a significant source of positive cash flow.
The company is actively pursuing a growth strategy through clinic acquisitions and expansion, complementing its INVOcell device sales.
INVOcell technology offers a lower-cost, more natural, and intimate intravaginal culture (IVC) procedure with comparable pregnancy success rates to traditional IVF.

Negatives

The S-1 filing is for the resale of shares by existing stockholders, meaning the company will not receive direct proceeds from these sales.
The potential sale of up to 7,372,122 shares by selling stockholders could cause substantial dilution to existing stockholders and a decline in the common stock's trading price.
The company's auditor, M&K CPAs, PLLC, included an explanatory paragraph in their report regarding the company's ability to continue as a going concern.
The conversion price of Series C-2 Preferred is subject to reduction, making the number of shares to be issued unpredictable and potentially leading to further dilution.
Investors purchasing shares at different times may experience different levels of dilution and investment outcomes due to varying prices and conversion adjustments.

Risks

Selling Stockholders may sell shares at prices below the current market price, which could adversely affect the market price of the common stock.
The actual number of Series C-2 Preferred shares sold under the Additional Investment Right to FNL and the gross proceeds may be less than $10 million, impacting future liquidity.
The conversion price per share of the Series C-2 Preferred is subject to reduction, making it impossible to predict the number of shares that will be sold and potentially leading to significant dilution.
The issuance of Common Stock upon exercise of Warrants and conversion of Series C-2 Preferred may cause substantial dilution to existing stockholders and a decline in the common stock price.
Management has broad discretion over the use of net proceeds from warrant exercises, and these funds may not be invested successfully, potentially harming the business or stock price.
The company may not realize the anticipated benefits or successfully integrate Family Beginnings' operations, personnel, technology, or assets.
There are significant conditions to closing the Family Beginnings acquisition, and it may not close as anticipated.
The Family Beginnings acquisition may prove to be worth less than paid and may not produce anticipated revenues, earnings, or cash flow.
The Family Beginnings acquisition could disrupt ongoing business, distract management, divert resources, and make it difficult to maintain current business standards, controls, and procedures.
The company may be unable to retain Family Beginnings' management and skilled employees.
Governmental actions could delay, condition, or prevent the completion of the Family Beginnings acquisition, or impose conditions that increase costs, limit operations, or reduce expected benefits.

Future Outlook

The company intends to continue its strategy of acquiring additional profitable IVF clinics and opening wholly-owned INVO Centers in the coming years to accelerate overall growth and expand its healthcare services within the fertility market. It also plans to seek out additional innovative fertility-focused technologies to license or acquire.

Management Comments

"We are a healthcare services and technology company focused on the fertility marketplace and dedicated to expanding access to assisted reproductive technology (ART) care for patients in need."
"The acquisition accelerated our expansion from a medical device company to a healthcare services company and immediately added scale and a significant source of positive cash flow to our operations." (Referring to the Wisconsin Fertility Institute acquisition)
"We believe dedicated INVO Centers require less investment than traditional IVF clinics and are operationally efficient, making them ideal for underserved secondary markets."
"We intend to use the net proceeds primarily for acquisitions of additional fertility clinics and related businesses, capital expenditures, working capital, and general and administrative expenses."

Industry Context

The company operates in the growing assisted reproductive technology (ART) market, aiming to expand access to fertility care. Its strategy of acquiring established, profitable IVF clinics and developing lower-cost INVO Centers positions it to address both high-end and underserved segments of the market. The INVOcell device offers a differentiated, more affordable alternative to traditional IVF, aligning with trends towards accessible and patient-centric healthcare solutions. The divestment of NAYA Therapeutics indicates a clear strategic focus on the fertility sector, streamlining operations and resource allocation.

Comparison to Industry Standards

The INVOcell IVC procedure is presented as delivering "comparable results at a lower cost than traditional IVF" and being "significantly more effective treatment than intrauterine insemination (IUI)," suggesting a competitive advantage in terms of cost-effectiveness and efficacy compared to established fertility treatments.
The acquisition of "profitable IVF clinics" like Wisconsin Fertility Institute (WFI) indicates a strategy to integrate successful existing models, which is a common industry practice for consolidation and market share expansion.
The development of "dedicated INVO Centers" that "require less investment than traditional IVF clinics and are operationally efficient" suggests a lean, scalable model potentially targeting markets or patient segments not fully served by larger, more capital-intensive IVF chains.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Director Liability	The company's Articles of Incorporation eliminate the personal liability of directors to the fullest extent permitted under Nevada Revised Statutes (NRS).	NA	Reduces personal risk for directors, potentially attracting and retaining board members, but may limit recourse for shareholders in cases of director misconduct not involving intentional acts or fraud.
Indemnification Policy	The company's Bylaws provide for indemnification of officers and directors to the fullest extent not prohibited by Nevada law, with certain conditions and exceptions.	NA	Protects officers and directors from liabilities and expenses incurred in their service, which is standard practice but can be costly for the company. The SEC views certain indemnification against public policy.
Expense Advancement	The company may advance expenses to officers and directors incurred in defending actions, subject to an undertaking to repay if not ultimately entitled to indemnification.	NA	Provides financial support for legal defense, ensuring officers and directors can defend themselves without immediate personal financial burden, but carries a contingent liability for the company.

Related Party Transactions

Five Narrow Lane LP (FNL) is a significant selling stockholder and has an "Additional Investment Right" to purchase up to $10 million in Series C-2 Preferred shares. FNL has engaged in multiple transactions with the company, including participation in offerings, inducement letter agreements, and various debenture exchanges and conversions of preferred stock.
Armistice Capital Master Fund Ltd. (Armistice) is a significant selling stockholder and participated in a private placement of approximately $4,000,000 in common stock and warrants. Armistice also participated in previous public offerings and amendments to securities purchase agreements.
Maxim Group LLC acted as the exclusive placement agent for the Private Placement, receiving an 8.0% fee and a Placement Agent Warrant for 118,343 shares issued to its affiliate, Maxim Partners LLC. Maxim Group LLC also acted as placement agent in previous offerings.
The acquisition of Family Beginnings involves James Donahue, MD, who is the sole owner, primary physician, medical director, and lab director of Family Beginnings. The transaction involves the issuance of preferred stock to Family Beginnings.

Stakeholder Impact

Shareholders face potential for significant dilution due to the large number of shares registered for resale and the exercise of warrants and conversion of preferred stock. The 'going concern' warning also poses a risk to shareholder value.
Employees of Family Beginnings may experience integration challenges and potential changes, including the risk of not retaining key personnel, following the acquisition.
Customers/Patients may benefit from increased access to ART care through the company's expansion via clinic acquisitions, potentially offering more options and affordable treatments (via INVOcell).
Creditors may raise concerns regarding the company's financial stability due to the 'going concern' warning. The extinguishment of the Second Amended and Restated Debenture with FNL is a positive for debt reduction.

Next Steps

Complete the acquisition of Family Beginnings by February 27, 2026.
Integrate Family Beginnings' operations, personnel, technology, and assets with existing operations.
Obtain stockholder approval to increase the number of authorized shares of Common Stock to 250,000,000 and to issue shares underlying the Common Warrant and Placement Agent Warrant as required by Nasdaq rules.
File an amendment to the Articles of Incorporation with the Nevada Secretary of State to increase authorized shares.
Continue building, acquiring, and operating fertility clinics (INVO Centers and IVF clinics).
Seek out additional innovative fertility-focused technologies to license or acquire.

Key Dates

Date	Description
2020-11-12	Description of common stock contained in registration statement on Form 8-A12B filed with the SEC.
2021-03-10	Established joint venture to open INVO Center in Birmingham, Alabama.
2021-06-28	Established joint venture to open INVO Center in Atlanta, Georgia.
2023-02	Issued 41 shares of Common Stock to consultants for services rendered.
2023-03-27	Issued common stock purchase warrants for 959 shares at $3,628.80/share to institutional investors and 26 shares at $5,163.84/share to placement agent.
2023-05	Issued 22 shares of Common Stock to consultants for services rendered.
2023-07	Issued 57 shares of Common Stock in consideration of a settlement with a third party.
2023-07-07	Entered into a securities purchase agreement (July 2023 SPA) with Armistice.
2023-08-08	Armistice participated in public offering of 1,580,000 units.
2023-08-10	Consummated acquisition of Wisconsin Fertility Institute (WFI).
2023-08-21	Issued 61 shares of Common Stock upon net-exercise of an existing warrant.
2023-09	Issued 26 shares of Common Stock to consultants for services rendered.
2023-11	Issued 26 shares of Common Stock to consultants for services rendered.
2024-01-03	FNL and NAYA Therapeutics Inc. entered into the January 2024 Securities Purchase Agreement.
2024-02	Issued 436 shares of Common Stock to consultants for services rendered.
2024-04	Issued 41 shares of Common Stock to consultants for services rendered.
2024-04-08	Consummated offering of FirstFire Note, Warrants, and Commitment Shares.
2024-Q2	Issued 382 shares of Common Stock upon conversion of $197,033 of convertible promissory notes.
2024-05	Issued 26 shares of Common Stock to consultants for services rendered.
2024-08	Issued 146 shares of Common Stock to consultants for services rendered.
2024-10	Acquired 100% interest in NAYA Therapeutics, Inc. (NTI).
2024-10	Issued 181 shares of Common Stock to consultants for services rendered.
2024-10	Issued 660 shares of Common Stock upon conversion of $190,000 of convertible promissory notes.
2024-10-11	Company became a party to the January 2024 Securities Purchase Agreement via a joinder agreement.
2025-01-14	FNL participated in the January 2025 Offering of 378,199 units.
2025-04-29	M&K CPAs, PLLC report dated for audit of consolidated financial statements as of December 31, 2024 and 2023.
2025-04-30	Entered into inducement letter agreement with FNL; issued warrants to purchase 29,115 shares of Common Stock at $38.64/share.
2025-05	Divested 80.1% ownership interest in NTI, returning to fertility focus; changed name and ticker to INVO Fertility, Inc. and IVF.
2025-05-23	Issued 2,054 shares of Series C-2 Preferred in exchange for Series C-1 Preferred Stock; issued Amended and Restated Senior Secured Convertible Debenture Due February 11, 2026.
2025-06-26	Institutional investor exercised right to acquire 500 shares of Series C-2 Preferred for $500,000 cash, adjusting conversion price to $22.80.
2025-06-30	FNL agreed to exercise Additional Investment Right to acquire 1,800 shares of Series C-2 Preferred ($1,800,000 stated value) in exchange for $1,800,000 principal of Amended and Restated Debenture; issued 630 shares of new unregistered Series C-2 Preferred to FNL.
2025-Q2	Issued an aggregate of 10,965 shares of Common Stock upon conversion of $250,000 in principal amount due under an amended and restated 7.0% debenture.
2025-07-17	Institutional investor exercised right to acquire 200 shares of Series C-2 Preferred for $200,000 cash, adjusting conversion price to $15.9624.
2025-07-21	Implemented a 1-for-3 reverse stock split.
2025-07-28	Institutional investor exercised right to acquire 200 shares of Series C-2 Preferred for $200,000 cash, adjusting conversion price to $15.1272; number of shares underlying warrants adjusted to 64,245, exercise price to $17.51.
2025-08-04	Institutional investor exercised right to acquire 200 shares of Series C-2 Preferred for $200,000 cash, adjusting conversion price to $12.272.
2025-08-14	Institutional investor exercised right to acquire 250 shares of Series C-2 Preferred for $250,000 cash, adjusting conversion price to $11.812.
2025-08-21	Entered into August 2025 FNL Amendment and Exchange Agreement; issued Second Amended and Restated Debenture in exchange for Amended and Restated Debenture; reduced outstanding principal by $1,300,000 in exchange for 1,300 Series C-2 Preferred shares; issued 325 additional Series C-2 Preferred shares.
2025-08-28	Institutional investor exercised right to acquire 200 shares of Series C-2 Preferred for $200,000 cash, adjusting conversion price to $7.1136.
2025-09-08	Institutional investor exercised right to acquire 200 shares of Series C-2 Preferred for $200,000 cash, adjusting conversion price to $5.8896.
2025-09-29	FNL exchanged Second Amended and Restated Debenture for 1,334 shares of Series C-2 Preferred ($1,334,000 stated value); issued 467 additional Series C-2 Preferred shares; Second Amended and Restated Debenture fully extinguished.
2025-09-30	Institutional investor exercised right to acquire 400 shares of Series C-2 Preferred for $400,000 cash, adjusting conversion price to $5.7128.
2025-10-06	Institutional investor exercised right to acquire 200 shares of Series C-2 Preferred for $200,000 cash, adjusting conversion price to $5.3144.
2025-10-16	Institutional investor exercised right to acquire 500 shares of Series C-2 Preferred for $500,000 cash, adjusting conversion price to $5.028.
2025-11-28	1-for-8 reverse stock split became effective for trading; conversion price of Series C-2 Preferred adjusted to $4.896 per share.
2025-12-02	Entered into Securities Purchase Agreement with Armistice for Private Placement; entered into Placement Agency Agreement with Maxim Group LLC.
2025-12-03	Issued securities in private placement to Armistice (235,000 common shares, prefunded warrants for 2,131,864 shares, common warrants for 4,733,728 shares); issued placement agent warrants to Maxim Group LLC for 118,343 shares.
2025-12-05	Number of shares underlying warrants adjusted to 216,833, exercise price to $1.4898, following Reverse Split.
2025-12-12	Entered into asset purchase agreement to acquire Family Beginnings for $750,000.
2025-12-16	Last reported sale price for common stock on Nasdaq was $1.18 per share; 2,386,826 shares of Common Stock outstanding.
2025-12-17	Filing date of the S-1 Registration Statement.
2026-01-31	If Family Beginnings acquisition closes after this date, cash portion of purchase price increases by $10,000.
2026-02-11	Maturity date of Second Amended and Restated Senior Secured Convertible Debenture (now fully extinguished).
2026-02-27	Expected closing date for the Family Beginnings acquisition; Asset Purchase Agreement automatically terminates if closing does not occur by this date, unless extended.

Recommendation

sell

The S-1 filing highlights significant risks that outweigh the strategic positives. The primary purpose of the filing is to register a large number of shares (over 7.3 million) for resale by existing stockholders, which is more than three times the currently outstanding shares (2.38 million). This substantial potential dilution, coupled with the auditor's 'going concern' warning, signals considerable financial instability and likely downward pressure on the stock price. While the acquisition of Family Beginnings is a strategic expansion, its benefits are prospective and subject to integration risks, and it does not mitigate the immediate and severe dilution risk. A seasoned investor would likely view the current situation as highly unfavorable, suggesting a 'sell' recommendation to avoid further potential losses from dilution and financial uncertainty.

Keywords

fertility, IVF, INVOcell, ART, healthcare services, medical device, clinic acquisition, S-1 filing, common stock, warrants, private placement, dilution, Nasdaq

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.